Skip to main content
SpringerLink
Log in

Mitochondrial Symptomatic Treatments

  • Chapter
  • First Online:
Diagnosis and Management of Mitochondrial Disorders

Abstract

Based on improvements in diagnostic strategies, the group of genetically defined mitochondrial diseases is rapidly growing. This advances our understanding of the underlying pathophysiology and is important for genetic counseling of affected families. However, despite numerous research efforts, treatment strategies that truly affect disease progression are mostly unavailable. Therefore, symptomatic therapy still plays a key role in the management of most individuals suffering from mitochondrial diseases. In this context, it is important to realize that mitochondrial diseases frequently affect multiple organ systems, which requires multidisciplinary treatment concepts. Here, we will give an overview of several key problems in mitochondrial disease patients that can benefit from symptomatic treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Koopman WJ, Beyrath J, Fung CW, Koene S, Rodenburg RJ, Willems PH, Smeitink JA. Mitochondrial disorders in children: toward development of small-molecule treatment strategies. EMBO Mol Med. 2016;8:311–27.

    Article  CAS  Google Scholar 

  2. Whittaker RG, Devine HE, Gorman GS, Schaefer AM, Horvath R, Ng Y, Nesbitt V, Lax NZ, McFarland R, Cunningham MO, Taylor RW, Turnbull DM. Epilepsy in adults with mitochondrial disease: a cohort study. Ann Neurol. 2015;78:949–57.

    Article  CAS  Google Scholar 

  3. Li S, Guo J, Ying Z, Chen S, Yang L, Chen K, Long Q, Qin D, Pei D, Liu X. Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model. Hepatology. 2015;61:1730–9.

    Article  CAS  Google Scholar 

  4. Finsterer J, Zarrouk Mahjoub S. Epilepsy in mitochondrial disorders. Seizure. 2012;21:316–21.

    Article  Google Scholar 

  5. Finsterer J, Scorza FA. Effects of antiepileptic drugs on mitochondrial functions, morphology, kinetics, biogenesis, and survival. Epilepsy Res. 2017;136:5–11.

    Article  CAS  Google Scholar 

  6. Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741–53. https://doi.org/10.1136/jnnp-2017-317168.

    Article  PubMed  Google Scholar 

  7. Scholl-Bürgi S, Höller A, Pichler K, Michel M, Haberlandt E, Karall D. Ketogenic diets in patients with inherited metabolic disorders. J Inherit Metab Dis. 2015;38:765–73.

    Article  Google Scholar 

  8. Koy A, Lin JP, Sanger TD, Marks WA, Mink JW, Timmermann L. Advances in management of movement disorders in children. Lancet Neurol. 2016;15:719–35.

    Article  Google Scholar 

  9. Auré K, Dubourg O, Jardel C, Clarysse L, Sternberg D, Fournier E, Laforêt P, Streichenberger N, Petiot P, Gervais-Bernard H, Vial C, Bedat-Millet AL, Drouin-Garraud V, Bouillaud F, Vandier C, Fontaine B, Lombès A. Episodic weakness due to mitochondrial DNA MT-ATP6/8 mutations. Neurology. 2013;81:1810–8.

    Article  Google Scholar 

  10. Danhauser K, Smeitink JA, Freisinger P, Sperl W, Sabir H, Hadzik B, Mayatepek E, Morava E, Distelmaier F. Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease. J Inherit Metab Dis. 2015;38:467–75.

    Article  CAS  Google Scholar 

  11. Aubry E, Aeberhard C, Bally L, Nuoffer JM, Risch L, Mühlebach S, Burgunder JM, Stanga Z. Are patients affected by mitochondrial disorders at nutritional risk? Nutrition. 2018;47:56–62.

    Article  CAS  Google Scholar 

  12. Distelmaier F, Haack TB, Wortmann SB, Mayr JA, Prokisch H. Treatable mitochondrial diseases: cofactor metabolism and beyond. Brain. 2017;140:e11.

    Article  Google Scholar 

  13. Herebian D, López LC, Distelmaier F. Bypassing human CoQ10 deficiency. Mol Genet Metab. 2018;123:289–91.

    Article  CAS  Google Scholar 

  14. Infante JP, Huszagh VA. Secondary carnitine deficiency and impaired docosahexaenoic (22:6n-3) acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett. 2000;468:1–5.

    Article  CAS  Google Scholar 

  15. Kraya T, Deschauer M, Joshi PR, Zierz S, Gaul C. Prevalence of headache in patients with mitochondrial disease: a cross-sectional study. Headache. 2018;58:45–52.

    Article  Google Scholar 

  16. Fumal A, Schoenen J. Tension-type headache: current research and clinical management. Lancet Neurol. 2008;7:70–83.

    Article  CAS  Google Scholar 

  17. Finsterer J, Zarrouk-Mahjoub S. Headache in mitochondrial disorders. Clin Neurol Neurosurg. 2018;166:44–9.

    Article  Google Scholar 

  18. Ganetzky RD, Falk MJ. 8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease. Mol Genet Metab. 2018;123:301–8.

    Article  CAS  Google Scholar 

  19. Koenig MK, Emrick L, Karaa A, Korson M, Scaglia F, Parikh S, Goldstein A. Recommendations for the management of strokelike episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes. JAMA Neurol. 2016;73:591–4.

    Article  Google Scholar 

  20. Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Tanabe Y, Fujimoto S, Matsuishi T. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology. 2005;64:710–2.

    Article  CAS  Google Scholar 

  21. Fryer RH, Bain JM, De Vivo DC. Mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS): a case report and critical reappraisal of treatment options. Pediatr Neurol. 2016;56:59–61.

    Article  Google Scholar 

  22. Hirano M. Mitochondrial neurogastrointestinal encephalopathy disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993–2018; 2005. [updated 2016 Jan 14]

    Google Scholar 

  23. Halter J, Schüpbach W, Casali C, Elhasid R, Fay K, Hammans S, Illa I, Kappeler L, Krähenbühl S, Lehmann T, Mandel H, Marti R, Mattle H, Orchard K, Savage D, Sue CM, Valcarcel D, Gratwohl A, Hirano M. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant. 2011;46:330–7.

    Article  CAS  Google Scholar 

  24. Baertling F, Meissner T, Troeger A, Pillekamp F, Mayatepek E, Laws HJ, Distelmaier F. Granulocyte colony stimulating factor for treatment of neutropenia-associated infection in Pearson syndrome. Klin Padiatr. 2014;226:190–1.

    Article  CAS  Google Scholar 

  25. Chow J, Rahman J, Achermann JC, Dattani MT, Rahman S. Mitochondrial disease and endocrine dysfunction. Nat Rev Endocrinol. 2017;13:92–104.

    Article  CAS  Google Scholar 

  26. Schaefer AM, Walker M, Turnbull DM, Taylor RW. Endocrine disorders in mitochondrial disease. Mol Cell Endocrinol. 2013;379:2–11.

    Article  CAS  Google Scholar 

  27. Emma F, Salviati L. Mitochondrial cytopathies and the kidney. Nephrol Ther. 2017;13(Suppl 1):S23–8.

    Article  Google Scholar 

  28. Herebian D, Seibt A, Smits SHJ, Rodenburg RJ, Mayatepek E, Distelmaier F. 4-Hydroxybenzoic acid restores CoQ10 biosynthesis in human COQ2 deficiency. Ann Clin Transl Neurol. 2017;4:902–8.

    Article  CAS  Google Scholar 

  29. Martín-Hernández E, García-Silva MT, Vara J, Campos Y, Cabello A, Muley R, Del Hoyo P, Martín MA, Arenas J. Renal pathology in children with mitochondrial diseases. Pediatr Nephrol. 2005;20:1299–305.

    Article  Google Scholar 

  30. Yelverton JC, Arnos K, Xia XJ, Nance WE, Pandya A, Dodson KM. The clinical and audiologic features of hearing loss due to mitochondrial mutations. Otolaryngol Head Neck Surg. 2013;148:1017–22.

    Article  Google Scholar 

  31. El-Hattab AW, Scaglia F. Mitochondrial cardiomyopathies. Front Cardiovasc Med. 2016;3:25.

    Article  Google Scholar 

  32. Lee TM, Hsu DT, Kantor P, Towbin JA, Ware SM, Colan SD, Chung WK, Jefferies JL, Rossano JW, Castleberry CD, Addonizio LJ, Lal AK, Lamour JM, Miller EM, Thrush PT, Czachor JD, Razoky H, Hill A, Lipshultz SE. Pediatric cardiomyopathies. Circ Res. 2017;121:855–73.

    Article  CAS  Google Scholar 

  33. Finsterer J, Mancuso M, Pareyson D, Burgunder JM, Klopstock T. Mitochondrial disorders of the retinal ganglion cells and the optic nerve. Mitochondrion. 2018;42:1–10. https://doi.org/10.1016/j.mito.2017.10.003.

    Article  CAS  PubMed  Google Scholar 

  34. Morava E, Gardeitchik T, Kozicz T, de Boer L, Koene S, de Vries MC, McFarland R, Roobol T, Rodenburg RJ, Verhaak CM. Depressive behaviour in children diagnosed with a mitochondrial disorder. Mitochondrion. 2010;10:528–33.

    Article  CAS  Google Scholar 

  35. Ayyash HF, Preece P, Morton R, Cortese S. Melatonin for sleep disturbance in children with neurodevelopmental disorders: prospective observational naturalistic study. Expert Rev Neurother. 2015;15:711–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Faculty, Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children’s Hospital, Heinrich-Heine-University, Düsseldorf, Germany

    Felix Distelmaier

  2. Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University of Munich, Munich, Germany

    Thomas Klopstock

  3. German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

    Thomas Klopstock

  4. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

    Thomas Klopstock

Authors
  1. Felix Distelmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Klopstock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felix Distelmaier .

Editor information

Editors and Affiliations

  1. Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, Pisa, Italy

    Michelangelo Mancuso

  2. Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University of Munich, Munich, Germany

    Thomas Klopstock

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Distelmaier, F., Klopstock, T. (2019). Mitochondrial Symptomatic Treatments. In: Mancuso, M., Klopstock, T. (eds) Diagnosis and Management of Mitochondrial Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-05517-2_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-05517-2_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-05516-5

  • Online ISBN: 978-3-030-05517-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation